{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:06:51Z","timestamp":1792019211499,"version":"4.4.0"},"reference-count":239,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Hepatic malignancies are a major global health burden, with rising incidence, high mortality, and frequent diagnosis at advanced or unresectable stages. Although surgical resection, locoregional therapies, and systemic treatments have improved outcomes, many patients remain ineligible for curative strategies because of tumor burden, anatomical constraints, or liver dysfunction. Liver transplantation (LT) has therefore evolved from a treatment limited to selected hepatocellular carcinoma (HCC) cases within strict morphological criteria to a broader oncologic option guided by tumor biology and treatment response. This review provides an updated overview of the expanding role of LT in hepatic malignancies and the transition toward precision transplant oncology. Methods: We conducted a narrative review of current evidence on LT in HCC, cholangiocarcinoma (CCA), and colorectal liver metastases (CRLM), focusing on candidate selection, neoadjuvant strategies, molecular profiling, immunological aspects, and future perspectives. Results: In HCC, expanded criteria and bridging\/downstaging strategies, including immunotherapy, have increased transplant eligibility, although concerns remain regarding rejection risk and post-transplant management. In CCA, especially perihilar disease, standardized neoadjuvant protocols followed by LT have achieved encouraging long-term survival in highly selected patients, whereas intrahepatic CCA remains investigational within prospective biomarker-driven studies. In CRLM, once considered an absolute contraindication, recent evidence supports LT in selected patients with liver-confined and biologically favorable disease, emphasizing the importance of tumor kinetics, molecular features, and response to systemic therapy. Conclusions: Integration of molecular oncology, immunology, and advanced therapies is redefining LT indications for hepatic malignancies. Future progress will depend on biomarker-driven selection, precision medicine, and multidisciplinary decision-making to optimize outcomes while addressing ethical challenges in organ allocation.<\/jats:p>","DOI":"10.3390\/jcm15103579","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:15:07Z","timestamp":1778156107000},"page":"3579","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-9019","authenticated-orcid":false,"given":"Mario","family":"Romeo","sequence":"first","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0519-3049","authenticated-orcid":false,"given":"Fiammetta","family":"Di Nardo","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2392-3539","authenticated-orcid":false,"given":"Carmine","family":"Napolitano","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vaia","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5473-3440","authenticated-orcid":false,"given":"Claudio","family":"Basile","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Senese","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4818-9714","authenticated-orcid":false,"given":"Annachiara","family":"Coppola","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2862-7619","authenticated-orcid":false,"given":"Patrizia","family":"Iodice","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, AORN Azienda dei Colli, Monaldi Hospital, via Leonardo Bianchi, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Olivieri","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0885-0793","authenticated-orcid":false,"given":"Alessandro","family":"Federico","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-815X","authenticated-orcid":false,"given":"Marcello","family":"Dallio","sequence":"additional","affiliation":[{"name":"Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Piazza Miraglia 2, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global Burden of Primary Liver Cancer in 2020 and Predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, Regional and National Burden of Primary Liver Cancer by Subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101271","DOI":"10.1016\/j.jhepr.2024.101271","article-title":"Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease, 2010 to 2021","volume":"7","author":"Feng","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/liv.14087","article-title":"Characteristics and Outcome of Hepatocellular Carcinoma in Patients with NAFLD without Cirrhosis","volume":"39","author":"Bengtsson","year":"2019","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next Horizon in Mechanisms and Management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma","volume":"145","author":"Ilyas","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1097\/MD.0000000000000868","article-title":"Primary Squamous Cell Carcinoma of Liver: Case Series and Review of Literatures","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3892\/ol.2025.15025","article-title":"Immunotherapy for Primary Squamous Cell Carcinoma of the Liver: A Case Report","volume":"29","author":"Jiang","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107655","DOI":"10.1016\/j.ijscr.2022.107655","article-title":"Primary Squamous Cell Carcinoma of Liver. First Case Report from Pakistan and South Asia","volume":"99","author":"Atiq","year":"2022","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_10","unstructured":"Griscom, J.T., and Wolf, P.S. (2026). Liver Metastasis. StatPearls, StatPearls Publishing."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.5858\/2008-132-931-MPOCRF","article-title":"Metastatic Patterns of Cancers: Results From a Large Autopsy Study","volume":"132","author":"Disibio","year":"2008","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Finotti, M., D\u2019Amico, F.E., Romano, M., Brizzolari, M., Scopelliti, M., and Zanus, G. (2022). Colorectal Liver Metastases: A Literature Review of Viable Surgical Options with a Special Focus on Microwave Liver Thermal Ablation and Mini-Invasive Approach. J. Pers. Med., 13.","DOI":"10.3390\/jpm13010033"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00384-015-2323-6","article-title":"Negative Surgical Margin Improved Long-Term Survival of Colorectal Cancer Liver Metastases after Hepatic Resection: A Systematic Review and Meta-Analysis","volume":"30","author":"Liu","year":"2015","journal-title":"Int. J. Color. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.14701\/ahbps.24-233","article-title":"A Positive Resection Margin Does Not Determine Long-Term Survival Following Colorectal Liver Metastasis Resection","volume":"29","author":"Konstantinou","year":"2025","journal-title":"Ann. Hepato-Biliary-Pancreat. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000658-200204000-00004","article-title":"Locoregional Therapies for Hepatocellular Carcinoma: A Critical Review From the Surgeon\u2019s Perspective","volume":"235","author":"Poon","year":"2002","journal-title":"Ann. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.17998\/jlc.2024.01.31","article-title":"Liver Resection in Selective Hepatocellular Carcinoma with Vp3 or Vp4 Portal Vein Tumor Thrombosis Improves Prognosis","volume":"24","author":"Lim","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1111\/ans.14708","article-title":"Nomogram Predicting Survival of Hepatocellular Carcinoma with Portal Vein Tumour Thrombus after Curative Resection","volume":"89","author":"Hu","year":"2019","journal-title":"ANZ J. Surg."},{"key":"ref_18","first-page":"294","article-title":"The Role of Toll-like Receptors in Liver Regeneration after Partial Hepatectomy","volume":"20","author":"Dritsas","year":"2025","journal-title":"Prz. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41392-024-02104-8","article-title":"Molecular Mechanisms in Liver Repair and Regeneration: From Physiology to Therapeutics","volume":"10","author":"Ma","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semcancer.2020.09.008","article-title":"Limitations in Resectability of Colorectal Liver Metastases 2020\u2014A Systematic Approach for Clinicians and Patients","volume":"71","author":"Schadde","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1477-2574.2012.00597.x","article-title":"Locoregional Surgical and Interventional Therapies for Advanced Colorectal Cancer Liver Metastases: Expert Consensus Statements","volume":"15","author":"Abdalla","year":"2013","journal-title":"HPB"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/EDBK_320519","article-title":"Locoregional Therapies for Colorectal Cancer Liver Metastases: Options Beyond Resection","volume":"Volume 41","author":"Uhlig","year":"2021","journal-title":"American Society Of Clinical Oncology Educational Book"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jvir.2014.08.027","article-title":"Image-Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria\u2014A 10-Year Update","volume":"25","author":"Ahmed","year":"2014","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sergi, C.M. (2021). Locoregional Therapies for Bridging and Downstaging Hepatocellular Carcinoma Prior to Liver Transplant. Liver Cancer, Exon Publications.","DOI":"10.36255\/exonpublications.livercancer.2021"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ejso.2019.12.003","article-title":"Systematic Review and Meta-Analysis of Local Ablative Therapies for Resectable Colorectal Liver Metastases","volume":"46","author":"Rompianesi","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_26","first-page":"461","article-title":"Hepatocolic Fistula after Ablative Radiation Lobectomy of a Right Lobe Colorectal Liver Metastasis","volume":"20","author":"Dimopoulos","year":"2025","journal-title":"Prz. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.radonc.2010.07.019","article-title":"Clinical Evidence on PET-CT for Radiation Therapy Planning in Gastro-Intestinal Tumors","volume":"96","author":"Lambrecht","year":"2010","journal-title":"Radiother. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO Consensus Guidelines for the Management of Patients with Metastatic Colorectal Cancer","volume":"27","author":"Cervantes","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"726\u2013734; discussion 734\u2013735","article-title":"Hepatic Transplantation for Primary and Metastatic Cancers of the Liver","volume":"110","author":"Penn","year":"1991","journal-title":"Surgery"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jhep.2023.04.008","article-title":"Donation after Circulatory Death: Novel Strategies to Improve the Liver Transplant Outcome","volume":"78","author":"Muiesan","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Romic, I., Mijatovic, D., Petrovic, I., Vrbanovic Mijatovic, V., Pavlek, G., Strajher, I.M., Silic, V., Jericevic, K., Kolak, J., and Basic, J. (2025). Liver Machine Perfusion: Past, Present and Future Directions. Biomedicines, 13.","DOI":"10.3390\/biomedicines13112729"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1111\/j.1600-6143.2008.02351.x","article-title":"Liver Transplantation for Hepatocellular Carcinoma: Beyond the Milan Criteria","volume":"8","author":"Yao","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1111\/j.1600-6143.2007.01965.x","article-title":"Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging","volume":"7","author":"Yao","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3350\/cmh.2025.0986","article-title":"Network Meta-Analysis and Validation Study of Expanded Liver Transplantation Criteria for HCC: Significant Role of AFP","volume":"32","author":"Yu","year":"2026","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"96687","DOI":"10.5500\/wjt.v14.i4.96687","article-title":"Ethical Frontiers in Liver Transplantation","volume":"14","author":"Wong","year":"2024","journal-title":"World J. Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2024). EASL Clinical Practice Guidelines on Liver Transplantation. J. Hepatol., 81, 1040\u20131086.","DOI":"10.1016\/j.jhep.2024.07.032"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD Guidelines for the Treatment of Hepatocellular Carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/SLA.0000000000006049","article-title":"Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria: A Multicentric North American Experience","volume":"279","author":"Ivanics","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine Induces Cancer Progression by a Cell-Autonomous Mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/jlts.2002.35927","article-title":"The New Liver Allocation System: Moving toward Evidence-Based Transplantation Policy","volume":"8","author":"Freeman","year":"2002","journal-title":"Liver Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/SLA.0000000000000786","article-title":"Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer?","volume":"261","author":"Dueland","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","article-title":"Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer","volume":"257","author":"Hagness","year":"2013","journal-title":"Ann. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","article-title":"Survival Following Liver Transplantation for Patients with Nonresectable Liver-Only Colorectal Metastases","volume":"271","author":"Dueland","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/lt.24791","article-title":"Liver Transplantation for Colorectal Liver Metastasis: Survival without Recurrence Can Be Achieved","volume":"23","author":"Toso","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ccell.2017.12.004","article-title":"Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer","volume":"33","author":"Yaeger","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000141198.92114.f6","article-title":"Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-Term Survival","volume":"240","author":"Adam","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma","volume":"154","author":"Mazzaferro","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ilmer, M., and Guba, M. (2022). Liver Transplant Oncology: Towards Dynamic Tumor-Biology-Oriented Patient Selection. Cancers, 14.","DOI":"10.3390\/cancers14112662"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Zhang, C., Yuan, X., and Xie, K. (2025). Immunological Crossroads: Optimizing Antirejection Regimens to Sustain Antitumor Immunity in Liver Transplant Recipients with Hepatocellular Carcinoma. Cancers, 17.","DOI":"10.3390\/cancers17233871"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kim, S.H. (2025). Transforming Liver Cancer Therapy: Integrating Molecular Profiling with Precision and Transplant-Based Care. Cancers, 17.","DOI":"10.3390\/cancers17223671"},{"key":"ref_55","first-page":"221","article-title":"The Role of Artificial Intelligence and Image Processing in the Diagnosis, Treatment, and Prognosis of Liver Cancer: A Narrative-Review","volume":"19","author":"Dimopoulos","year":"2024","journal-title":"Prz. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00261-025-05059-8","article-title":"Artificial Intelligence in Imaging Diagnosis of Liver Tumors: Current Status and Future Prospects","volume":"51","author":"Hori","year":"2026","journal-title":"Abdom. Radiol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Romeo, M., Dallio, M., Napolitano, C., Basile, C., Di Nardo, F., Vaia, P., Iodice, P., and Federico, A. (2025). Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?. Diagnostics, 15.","DOI":"10.3390\/diagnostics15030252"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/LVT.0000000000000685","article-title":"Machine Learning Improves Post-Transplantation HCC Recurrence Prediction","volume":"31","author":"Li","year":"2025","journal-title":"Liver Transplant."},{"key":"ref_59","first-page":"327","article-title":"Hypoglycemia with Primary Liver Cell Carcinoma","volume":"21","author":"Mehta","year":"1973","journal-title":"J. Assoc. Physicians India"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Kalista, K.F., Rahma, H.C.N., Tahapary, D.L., Nababan, S.H., Jasirwan, C.O.M., Kurniawan, J., Lesmana, C.R.A., Sulaiman, A.S., Hasan, I., and Gani, R. (2024). Persistent Hypoglycemia in Patients with Liver Cancer. Endocrinol. Diabetes Metab. Case Rep., 2024.","DOI":"10.1530\/EDM-23-0077"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","article-title":"Combination Immunotherapy in Hepatocellular Carcinoma: Synergies among Immune Checkpoints, TKIs, and Chemotherapy","volume":"18","author":"Dai","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Dallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A.D., Loguercio, C., Serviddio, G., and Federico, A. (2021). Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010436"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Romeo, M., Dallio, M., Di Nardo, F., Napolitano, C., Vaia, P., Martinelli, G., Federico, P., Olivieri, S., Iodice, P., and Federico, A. (2025). The Role of the Gut\u2013Biliary\u2013Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications. J. Pers. Med., 15.","DOI":"10.3390\/jpm15040124"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Romeo, M., Silvestrin, A., Senese, G., Di Nardo, F., Napolitano, C., Vaia, P., Coppola, A., Federico, P., Dallio, M., and Federico, A. (2025). From \u201cTraditional\u201d to \u201cTrained\u201d Immunity: Exploring the Novel Frontiers of Immunopathogenesis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Biomedicines, 13.","DOI":"10.3390\/biomedicines13082004"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3892\/ol.2025.15322","article-title":"Immune Checkpoint Biology in Hepatocellular Carcinoma (Review)","volume":"30","author":"Hsieh","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and Non-Inflamed Classes of HCC: A Revised Immunogenomic Classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Abdelrahim, M., Esmail, A., Abudayyeh, A., Murakami, N., Victor, D., Kodali, S., Cheah, Y.L., Simon, C.J., Noureddin, M., and Connor, A. (2023). Transplant Oncology: An Emerging Discipline of Cancer Treatment. Cancers, 15.","DOI":"10.3390\/cancers15225337"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC Strategy for Prognosis Prediction and Treatment Recommendation: The 2022 Update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A Moving Target in Immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_72","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kudo, M. (2020). Scientific Rationale for Combined Immunotherapy with PD-1\/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers, 12.","DOI":"10.3390\/cancers12051089"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Khalaf, M.H., Tran, B., Krendl, F., Doan, T., Rachko, J., Marino, R., and Tabrizian, P. (Hepatobiliary Pancreat. Dis. Int., 2025). Hepatocellular Carcinoma and Liver Transplant: What about Neo- and Adjuvant Immunotherapy, Hepatobiliary Pancreat. Dis. Int., in press.","DOI":"10.1016\/j.hbpd.2025.10.004"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e0158","DOI":"10.1097\/CLD.0000000000000158","article-title":"Approach to Immunotherapy for HCC in the Liver Transplant Population","volume":"23","author":"Block","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1200\/JCO.2025.43.16_suppl.4135","article-title":"Effect of the Combination of Systemic and Locoregional Therapy on Tumor Recurrence and Survival after Liver Transplantation for Hepatocellular Carcinoma (HCC)","volume":"43","author":"Nanneboyina","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"101246","DOI":"10.1016\/j.jhepr.2024.101246","article-title":"Neoadjuvant Atezolizumab plus Bevacizumab Prior Liver Transplantation for Hepatocellular Carcinoma","volume":"7","author":"Tabrizian","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus Ipilimumab for Potentially Resectable Hepatocellular Carcinoma: Long-Term Efficacy and Biomarker Exploration","volume":"84","author":"Lin","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e1852","DOI":"10.1097\/TXD.0000000000001852","article-title":"Pretransplant Immune Checkpoint Inhibitor Treatment for Intermediate-Advanced Hepatocellular Carcinoma in Living Donor Liver Transplantation","volume":"11","author":"Cheng","year":"2025","journal-title":"Transplant. Direct"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Fang, J., Zhong, S., Wang, T., He, K., Mu, A., Ong, M., Lin, Y., Zhu, Z., Wang, N., and Wu, J. (2025). Immune-Related Adverse Events Are a Potent Predictor of Post-Transplant Rejection in HCC: A Multicentre Retrospective Cohort Study. Gut, Epub ahead of printing.","DOI":"10.1136\/gutjnl-2025-336719"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/apt.70528","article-title":"Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma","volume":"63","author":"Aceituno","year":"2026","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Liu, D., Wang, X., Liu, X., and Li, J. (2025). Navigating the Risks: A Systematic Review of Immune Checkpoint Inhibitor Therapy before Liver Transplant for Hepatocellular Carcinoma and Its Impact on Allograft Rejection and Survival Outcomes. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1689820"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I Study of Single-Agent Anti\u2013Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ajt.15617","article-title":"Fatal Hepatic Necrosis after Nivolumab as a Bridge to Liver Transplant for HCC: Are Checkpoint Inhibitors Safe for the Pretransplant Patient?","volume":"20","author":"Nordness","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4285\/kjt.22.0013","article-title":"Immune Checkpoint Inhibitors for Solid Organ Transplant Recipients: Clinical Updates","volume":"36","author":"Kawashima","year":"2022","journal-title":"Korean J. Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41575-020-0334-4","article-title":"Understanding, Predicting and Achieving Liver Transplant Tolerance: From Bench to Bedside","volume":"17","author":"Thomson","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-6143.2009.02859.x","article-title":"PD-1\/B7-H1 Interaction Contribute to the Spontaneous Acceptance of Mouse Liver Allograft","volume":"10","author":"Morita","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.4049\/jimmunol.179.8.5204","article-title":"PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection","volume":"179","author":"Tanaka","year":"2007","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot Evaluation of PD-1 Inhibition in Metastatic Cancer Patients with a History of Liver Transplantation: The Mayo Clinic Experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e26682","DOI":"10.1002\/pbc.26682","article-title":"Fatal Orthotopic Liver Transplant Organ Rejection Induced by a Checkpoint Inhibitor in Two Patients with Refractory, Metastatic Hepatocellular Carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/ajt.16965","article-title":"Liver Transplantation for Hepatocellular Carcinoma Following Checkpoint Inhibitor Therapy with Nivolumab","volume":"22","author":"Schnickel","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"115373","DOI":"10.1016\/j.ejca.2025.115373","article-title":"Safety of Accelerated Infusion of Nivolumab and Pembrolizumab","volume":"220","author":"Nagtegaal","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant Use of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma: A Multicenter, Retrospective Cohort Study","volume":"24","author":"Guo","year":"2024","journal-title":"Am. J. Transplant."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.jhep.2024.07.025","article-title":"Strategic Timing and Patient Selection for ICIs Prior to Liver Transplantation for HCC","volume":"82","author":"Hao","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/lt.20391","article-title":"Analysis of Risk Factors for Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma: Key Role of Immunosuppression","volume":"11","author":"Vivarelli","year":"2005","journal-title":"Liver Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced Exposure to Calcineurin Inhibitors Early after Liver Transplantation Prevents Recurrence of Hepatocellular Carcinoma","volume":"59","author":"Tsochatzis","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.3390\/curroncol30060421","article-title":"The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma","volume":"30","author":"Todeschini","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus Use in Liver Transplant Recipients with Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","article-title":"mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients with Active Tumors","volume":"272","author":"Schnitzbauer","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.021908.132629","article-title":"The Liver as a Lymphoid Organ","volume":"27","author":"Crispe","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR Regulates Memory CD8 T-Cell Differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and Long-Term Outcomes in Kidney Transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A Pilot Study of Operational Tolerance with a Regulatory T-cell-based Cell Therapy in Living Donor Liver Transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.humimm.2017.10.007","article-title":"Tolerance in Clinical Liver Transplantation","volume":"79","author":"Levitsky","year":"2018","journal-title":"Hum. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5604\/01.3001.0012.2246","article-title":"Efficacy and Safety of Basiliximab as Initial Immunosuppression in Liver Transplantation: A Single Center Study","volume":"19","author":"Hashim","year":"2020","journal-title":"Ann. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Hussain, M.M., Wang, J.-M., Zhai, A.-Q., Li, F.-Y., and Hu, H.-J. (2025). Comparison of Prognostic Factors and Their Differences in Intrahepatic, Hilar, and Distal Cholangiocarcinoma: A Systematic Review and Meta-Analysis. World J. Gastrointest. Oncol., 17.","DOI":"10.4251\/wjgo.v17.i7.107995"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: Status Quo, Unmet Needs and Priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1055\/s-0044-1787171","article-title":"Liver Transplantation for Cholangiocarcinoma","volume":"8","author":"Soliman","year":"2024","journal-title":"Dig. Dis. Interv."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Esmail, A., Badheeb, M., Alnahar, B., Almiqlash, B., Sakr, Y., Khasawneh, B., Al-Najjar, E., Al-Rawi, H., Abudayyeh, A., and Rayyan, Y. (2024). Cholangiocarcinoma: The Current Status of Surgical Options Including Liver Transplantation. Cancers, 16.","DOI":"10.3390\/cancers16111946"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Hewitt, D.B., Brown, Z.J., and Pawlik, T.M. (2022). Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. Cancers, 14.","DOI":"10.3390\/cancers14092208"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"260","DOI":"10.7150\/thno.63417","article-title":"Driver Mutations of Intrahepatic Cholangiocarcinoma Shape Clinically Relevant Genomic Clusters with Distinct Molecular Features and Therapeutic Vulnerabilities","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/PO.18.00414","article-title":"Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients","volume":"4","author":"Cao","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting Co-Mutation Patterns Associated with Actionable Drivers in Intrahepatic Cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2024.42.16_suppl.4117","article-title":"Deep Immune Profiling of Intrahepatic Cholangiocarcinoma with CODEX Multiplexed Imaging","volume":"42","author":"Shekhar","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e0632","DOI":"10.1097\/HC9.0000000000000632","article-title":"Deep Immune Profiling of Intrahepatic Cholangiocarcinoma with CODEX Multiplexed Imaging","volume":"9","author":"Baretti","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1034\/j.1600-6143.2002.20812.x","article-title":"Radiochemotherapy and Transplantation Allow Long-Term Survival For Nonresectable Hilar Cholangiocarcinoma","volume":"2","author":"Sudan","year":"2002","journal-title":"Am. J. Transplant."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/lv.2000.6143","article-title":"Prolonged Disease-Free Survival after Orthotopic Liver Transplantation plus Adjuvant Chemoirradiation for Cholangiocarcinoma","volume":"6","author":"Steers","year":"2000","journal-title":"Liver Transpl."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2004-828896","article-title":"Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma","volume":"24","author":"Heimbach","year":"2004","journal-title":"Semin. Liver Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/13651820801992542","article-title":"Surgery for Cholangiocarcinoma: The Role of Liver Transplantation","volume":"10","author":"Rosen","year":"2008","journal-title":"HPB"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers","volume":"143","author":"Kim","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.21037\/jgo-2022-01","article-title":"Excellent Clinical Outcomes Can Be Achieved with Neoadjuvant Chemoradiation and Orthotopic Liver Transplantation for Unresectable Cholangiocarcinoma: Support for the Need of an International Transplant Protocol","volume":"13","author":"Laughlin","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"zrad025","DOI":"10.1093\/bjsopen\/zrad025","article-title":"Role of Neoadjuvant Chemoradiotherapy in Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma: Multicentre, Retrospective Cohort Study","volume":"7","author":"Hoogwater","year":"2023","journal-title":"BJS Open"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/COC.0000000000001002","article-title":"Neoadjuvant Therapy Regimens for Hilar Cholangiocarcinoma Before Liver Transplant","volume":"46","author":"Keltner","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1245\/s10434-020-09001-8","article-title":"Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma","volume":"28","author":"Vugts","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"znab117.037","DOI":"10.1093\/bjs\/znab117.037","article-title":"O37: SYSTEMATIC REVIEW AND PROPORTIONAL META-ANALYSIS OF SURVIVAL FOLLOWING NEOADJUVANT CHEMORADIATION AND LIVER TRANSPLANTATION IN UNRESECTABLE HILAR CHOLANGIOCARCINOMA","volume":"108","author":"Cambridge","year":"2021","journal-title":"Br. J. Surg."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/TP.0000000000003114","article-title":"Neoadjuvant Chemoradiotherapy and Liver Transplantation for Unresectable Hilar Cholangiocarcinoma: The Irish Experience of the Mayo Protocol","volume":"104","author":"Zaborowski","year":"2020","journal-title":"Transplantation"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s11605-020-04721-4","article-title":"Liver Transplantation for Peri-Hilar Cholangiocarcinoma","volume":"24","author":"Tan","year":"2020","journal-title":"J. Gastrointest. Surg."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Shaikh, A., Lee, T.-H., Lymberopoulos, P., Benhammou, J.N., Rich, N., Agobian, V.G., Hernaez, R., Goss, J., Singal, A.G., and El-Serag, H.B. (2025). Improved Liver Transplant Outcomes for Patients with Hilar Cholangiocarcinoma Following Implementation of the MMAT-3 Policy. Liver Transplant., Epub ahead of printing.","DOI":"10.1097\/LVT.0000000000000768"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jhbp.12121","article-title":"Safety and Efficacy of Living Donor Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma: A Single Center Prospective Study","volume":"32","author":"Ito","year":"2025","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/lt.26285","article-title":"A 3-Decade, Single-Center Experience of Liver Transplantation for Cholangiocarcinoma: Impact of Era, Tumor Size, Location, and Neoadjuvant Therapy","volume":"28","author":"Ito","year":"2022","journal-title":"Liver Transpl."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/jso.24833","article-title":"Neoadjuvant Hyperfractionated Chemoradiation and Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma in Canada","volume":"117","author":"Loveday","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.3390\/curroncol29050290","article-title":"Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series","volume":"29","author":"Abdelrahim","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver Transplantation for \u201cVery Early\u201d Intrahepatic Cholangiocarcinoma: International Retrospective Study Supporting a Prospective Assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"znaf054","DOI":"10.1093\/bjs\/znaf054","article-title":"Liver Transplantation for Locally Advanced Non-Resectable Intrahepatic Cholangiocarcinoma Treated with Neoadjuvant Therapy: Early Results from the TESLA Trial","volume":"112","author":"Yaqub","year":"2025","journal-title":"Br. J. Surg."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Maspero, M., Sposito, C., Bongini, M.A., Cascella, T., Flores, M., Maccauro, M., Chiesa, C., Niger, M., Pietrantonio, F., and Leoncini, G. (2024). Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study. Transpl. Int., 37.","DOI":"10.3389\/ti.2024.13641"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000545871","article-title":"Living Donor Liver Transplantation for Neoadjuvant-Treated, Unresectable Intrahepatic Cholangiocarcinoma (LIVINCA): Study Protocol for a One-Armed, Monocentric, Non-Randomized Trial","volume":"48","author":"Schwenk","year":"2025","journal-title":"Oncol. Res. Treat."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus Trametinib in Patients with BRAFV600E-Mutated Biliary Tract Cancer (ROAR): A Phase 2, Open-Label, Single-Arm, Multicentre Basket Trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ajt.2024.10.023","article-title":"Neoadjuvant Pemigatinib as a Bridge to Living Donor Liver Transplantation for Intrahepatic Cholangiocarcinoma with FGFR2 Gene Rearrangement","volume":"25","author":"Byrne","year":"2025","journal-title":"Am. J. Transplant."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast Growth Factor Signalling: From Development to Cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR Signaling in Cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of Antitumor T Cell Immunity by the Oncometabolite (R)-2-Hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1172\/JCI90644","article-title":"Isocitrate Dehydrogenase Mutations Suppress STAT1 and CD8+ T Cell Accumulation in Gliomas","volume":"127","author":"Kohanbash","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer Genome Landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc.2017.24","article-title":"Erratum: Consensus Molecular Subtypes and the Evolution of Precision Medicine in Colorectal Cancer","volume":"17","author":"Dienstmann","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1126\/science.aaf2784","article-title":"Metastasis as an Evolutionary Process","volume":"352","author":"Turajlic","year":"2016","journal-title":"Science"},{"key":"ref_149","first-page":"e153","article-title":"Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis","volume":"16","author":"Tosi","year":"2017","journal-title":"Clin. Color. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1245\/s10434-016-5609-1","article-title":"KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases","volume":"24","author":"Margonis","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging Biological Principles of Metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"key":"ref_152","first-page":"98","article-title":"The Distribution of Secondary Growths in Cancer of the Breast","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/0008-5472.CAN-12-3931","article-title":"The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications","volume":"73","author":"Majeed","year":"2013","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","article-title":"Analysis of Circulating Tumour DNA to Monitor Disease Burden Following Colorectal Cancer Surgery","volume":"65","author":"Reinert","year":"2016","journal-title":"Gut"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: Integrating Immunity\u2019s Roles in Cancer Suppression and Promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The Three Es of Cancer Immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International Validation of the Consensus Immunoscore for the Classification of Colon Cancer: A Prognostic and Accuracy Study","volume":"391","author":"Mlecnik","year":"2018","journal-title":"Lancet"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.immuni.2023.09.004","article-title":"Cancer Cell-Intrinsic Mechanisms Driving Acquired Immune Tolerance","volume":"56","author":"Ghorani","year":"2023","journal-title":"Immunity"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E\u2013Mutated Colorectal Cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The Consensus Molecular Subtypes of Colorectal Cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and Predictive Value of Primary Tumour Side in Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Chemotherapy and EGFR Directed Antibodies in Six Randomized Trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3904\/kjim.2016.348","article-title":"The Impact of Primary Tumor Location in Patients with Metastatic Colorectal Cancer: A Korean Cancer Study Group CO12-04 Study","volume":"34","author":"Byun","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1158\/1078-0432.CCR-16-0680","article-title":"Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry","volume":"23","author":"Trinh","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng.3225","article-title":"Stromal Gene Expression Defines Poor-Prognosis Subtypes in Colorectal Cancer","volume":"47","author":"Calon","year":"2015","journal-title":"Nat. Genet"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1053\/j.gastro.2009.10.057","article-title":"Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated with Survival in Colorectal Cancer","volume":"138","author":"Mlecnik","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and Cellular Insights into T Cell Exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/SLA.0b013e31824856f5","article-title":"Right Portal Vein Ligation Combined with In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings","volume":"255","author":"Schnitzbauer","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","article-title":"Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure","volume":"25","author":"Tomlinson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/SLA.0000000000001165","article-title":"A Novel Concept for Partial Liver Transplantation in Nonresectable Colorectal Liver Metastases: The RAPID Concept","volume":"262","author":"Line","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Cuadrado, A., Fortea, J.I., Rodr\u00edguez-Lope, C., Puente, \u00c1., Fern\u00e1ndez-Vilchez, V., Echavarria, V.J., Castillo Suescun, F.J., Fern\u00e1ndez, R., Echeverri, J.A., and Achalandabaso, M. (2023). Risk of Recurrence of Hepatocarcinoma after Liver Transplantation: Performance of Recurrence Predictive Models in a Cohort of Transplant Patients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175457"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Allkushi, E., Wehrle, C.J., Kim, J., Khalil, M., Kwon, D.C.H., Fujiki, M., Pinna, A.D., Miller, C., Schlegel, A., and Aucejo, F. (2025). Expanding Indications in Transplant Oncology. Cancers, 17.","DOI":"10.20944\/preprints202501.1458.v1"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.gassur.2024.09.006","article-title":"Outcomes of Liver Transplant for Colorectal Liver Metastasis: A Systematic Review and Meta-Analysis","volume":"28","author":"Dawood","year":"2024","journal-title":"J. Gastrointest. Surg."},{"key":"ref_177","first-page":"44","article-title":"Hepatocellular Carcinoma Recurrence after Liver Transplantation: Risk Factors, Targeted Surveillance and Management Options","volume":"10","author":"Pelizzaro","year":"2024","journal-title":"Hepatoma Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/hep4.1846","article-title":"Transcriptome and Exome Analyses of Hepatocellular Carcinoma Reveal Patterns to Predict Cancer Recurrence in Liver Transplant Patients","volume":"6","author":"Liu","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Zhu, G., Li, S., Luo, Z., Wen, N., Li, H., Fu, Y., Li, W., Wu, J., and Sun, X. (2025). Exploration Biomarkers for Recurrence of Hepatocellular Carcinoma After Liver Transplantation Based on Bioinformatics Analysis. Biochem. Genet., Epub ahead of printing.","DOI":"10.1007\/s10528-025-11227-8"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12014-021-09333-x","article-title":"Combined Proteomic\/Transcriptomic Signature of Recurrence Post-Liver Transplantation for Hepatocellular Carcinoma beyond Milan","volume":"18","author":"Bhat","year":"2021","journal-title":"Clin. Proteom."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41416-023-02213-1","article-title":"Liver Transplantation in Metastatic Colorectal Cancer: Are We Ready for It?","volume":"128","author":"Ros","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1097\/JS9.0000000000002280","article-title":"Predicting Futile Outcomes Following Deceased Donor Liver Transplantation in Non-HCC Patients with MELD-Na Score above 30: A Retrospective International Multicenter Cohort Study","volume":"111","author":"Jo","year":"2025","journal-title":"Int. J. Surg."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/hep.27272","article-title":"Standing the Test of Time: Outcomes of a Decade of Prioritizing Patients with Hepatocellular Carcinoma, Results of the UNOS Natural Geographic Experiment","volume":"60","author":"Halazun","year":"2014","journal-title":"Hepatology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s12029-020-00486-w","article-title":"The Importance of AFP in Liver Transplantation for HCC","volume":"51","author":"Baskiran","year":"2020","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.3390\/curroncol29100593","article-title":"Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future","volume":"29","author":"Ruch","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-Fetoprotein Level > 1000 Ng\/mL as an Exclusion Criterion for Liver Transplantation in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria","volume":"20","author":"Hameed","year":"2014","journal-title":"Liver Transplant."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gutjnl-2014-308513","article-title":"Liver Transplantation for Hepatocellular Carcinoma beyond the Milan Criteria","volume":"65","author":"Xu","year":"2016","journal-title":"Gut"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","article-title":"Liver Transplantation for Hepatocellular Carcinoma: A Model Including \u03b1-Fetoprotein Improves the Performance of Milan Criteria","volume":"143","author":"Duvoux","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2016.10.038","article-title":"Validation of the AFP Model as a Predictor of HCC Recurrence in Patients with Viral Hepatitis-Related Cirrhosis Who Had Received a Liver Transplant for HCC","volume":"66","author":"Notarpaolo","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/liv.13159","article-title":"Liver Transplantation for Hepatocellular Carcinoma: Evaluation of the Alpha-fetoprotein Model in a Multicenter Cohort from Latin America","volume":"36","author":"Marciano","year":"2016","journal-title":"Liver Int."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/TP.0000000000002136","article-title":"Validation of the \u03b1-Fetoprotein Model for Hepatocellular Carcinoma Recurrence After Transplantation in an Asian Population","volume":"102","author":"Rhu","year":"2018","journal-title":"Transplantation"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-6143.2009.02750.x","article-title":"Progression of Alphafetoprotein Before Liver Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients: A Critical Factor","volume":"10","author":"Vibert","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/hpb.12486","article-title":"Delta-slope of Alpha-fetoprotein Improves the Ability to Select Liver Transplant Patients with Hepatocellular Cancer","volume":"17","author":"Lai","year":"2015","journal-title":"HPB"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/SLA.0000000000002964","article-title":"Is It Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies","volume":"268","author":"Halazun","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jhep.2023.08.020","article-title":"AFP-L3 and DCP Strongly Predict Early Hepatocellular Carcinoma Recurrence after Liver Transplantation","volume":"79","author":"Norman","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ags3.12335","article-title":"Predictor of Outcome after Living Donor Liver Transplantation for Patients with Hepatocellular Carcinoma beyond the Japan Criteria","volume":"4","author":"Yonemura","year":"2020","journal-title":"Ann. Gastroent Surg."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Toniutto, P., Fumolo, E., Fornasiere, E., and Bitetto, D. (2021). Liver Transplantation in Patients with Hepatocellular Carcinoma beyond the Milan Criteria: A Comprehensive Review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173932"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.27752","article-title":"Downstaging of Hepatocellular Cancer before Liver Transplant: Long-term Outcome Compared to Tumors within Milan Criteria","volume":"61","author":"Yao","year":"2015","journal-title":"Hepatology"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.3350\/cmh.2024.0323","article-title":"Criteria and Prognostic Models for Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation","volume":"31","author":"Sha","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/tri.13586","article-title":"Liver Transplantation for Hepatocellular Carcinoma after Successful Treatment of Macrovascular Invasion\u2014A Multi-center Retrospective Cohort Study","volume":"33","author":"Assalino","year":"2020","journal-title":"Transpl. Int."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/hep.31210","article-title":"Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria","volume":"72","author":"Kardashian","year":"2020","journal-title":"Hepatology"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/SLA.0000000000003253","article-title":"Pathologic Response to Pretransplant Locoregional Therapy Is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium","volume":"271","author":"DiNorcia","year":"2020","journal-title":"Ann. Surg."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/tri.13153","article-title":"Impact of Remnant Vital Tissue after Locoregional Treatment and Liver Transplant in Hepatocellular Cancer Patients, a Multicentre Cohort Study","volume":"31","author":"Manzia","year":"2018","journal-title":"Transpl. Int."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/hep.30413","article-title":"Alpha-Fetoprotein Decrease from >1000 to <500 Ng\/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes","volume":"69","author":"Mehta","year":"2019","journal-title":"Hepatology"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3748\/wjg.v21.i10.3049","article-title":"Prognostic Value of 18F-FDG PET\/CT in Liver Transplantation for Hepatocarcinoma","volume":"21","author":"Detry","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3904\/kjim.2015.30.3.308","article-title":"Use of 18F-FDG PET to Predict Tumor Progression and Survival in Patients with Intermediate Hepatocellular Carcinoma Treated by Transarterial Chemoembolization","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J. Intern. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s12072-023-10511-2","article-title":"Development of a Deep Pathomics Score for Predicting Hepatocellular Carcinoma Recurrence after Liver Transplantation","volume":"17","author":"Qu","year":"2023","journal-title":"Hepatol. Int."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"101603","DOI":"10.1016\/j.tranon.2022.101603","article-title":"Immune Microenvironment and Therapeutic Progress of Recurrent Hepatocellular Carcinoma after Liver Transplantation","volume":"28","author":"Jin","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"63","DOI":"10.57603\/EJT-1749","article-title":"Non-tumor-related risks of post-transplant hepatocellular carcinoma (HCC) recurrence: A state-of-the-art review","volume":"3","author":"Pinto","year":"2025","journal-title":"Eur. J. Transplant."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Petrara, M.R., Shalaby, S., Ruffoni, E., Taborelli, M., Carmona, F., Giunco, S., Del Bianco, P., Piselli, P., Serraino, D., and Cillo, U. (2022). Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.899170"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"100846","DOI":"10.1016\/j.jhepr.2023.100846","article-title":"The Role of Ischaemia-Reperfusion Injury and Liver Regeneration in Hepatic Tumour Recurrence","volume":"5","author":"Maspero","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41419-023-05879-w","article-title":"FOXO1 Regulates Th17 Cell-Mediated Hepatocellular Carcinoma Recurrence after Hepatic Ischemia-Reperfusion Injury","volume":"14","author":"Ren","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12967-023-03977-z","article-title":"Hepatocyte SGK1 Activated by Hepatic Ischemia-Reperfusion Promotes the Recurrence of Liver Metastasis via IL-6\/STAT3","volume":"21","author":"Li","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"8935","DOI":"10.1038\/s41598-018-27319-y","article-title":"Ischemia-Reperfusion Injury and the Risk of Hepatocellular Carcinoma Recurrence after Deceased Donor Liver Transplantation","volume":"8","author":"Krawczyk","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3390\/curroncol31060221","article-title":"Oncologic Outcomes of Interventions to Decrease Allograft Ischemia-Reperfusion Injury within Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review","volume":"31","author":"Faleiro","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/hepr.12633","article-title":"Prognostic Prediction of Male Recipients Selected for Liver Transplantation: With Special Attention to Neutrophil to Lymphocyte Ratio","volume":"46","author":"Wang","year":"2016","journal-title":"Hepatol. Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/tri.12191","article-title":"Neutrophil and Platelet-to-Lymphocyte Ratio as New Predictors of Dropout and Recurrence after Liver Transplantation for Hepatocellular Cancer","volume":"27","author":"Lai","year":"2014","journal-title":"Transpl. Int."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1159\/000485396","article-title":"Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: A Meta-Analysis and Systematic Review","volume":"44","author":"Zheng","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in Cancer: Neutral No More","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_220","first-page":"269","article-title":"Prognostic Significance of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients Treated with Selective Internal Radiation Therapy","volume":"7","author":"Engelman","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Hong, H., Wehrle, C.J., Zhang, M., Fares, S., Stitzel, H., Garib, D., Estfan, B., Kamath, S., Krishnamurthi, S., and Ma, W.W. (2024). Circulating Tumor DNA Profiling in Liver Transplant for Hepatocellular Carcinoma, Cholangiocarcinoma, and Colorectal Liver Metastases: A Programmatic Proof of Concept. Cancers, 16.","DOI":"10.3390\/cancers16050927"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s12072-022-10348-1","article-title":"Preoperative Serum ctDNA Predicts Early Hepatocellular Carcinoma Recurrence and Response to Systemic Therapies","volume":"16","author":"Fu","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"e004656","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and Safety of Camrelizumab plus Apatinib during the Perioperative Period in Resectable Hepatocellular Carcinoma: A Single-Arm, Open Label, Phase II Clinical Trial","volume":"10","author":"Xia","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"Ye, K., Fan, Q., Yuan, M., Wang, D., Xiao, L., Long, G., Chen, R., Fang, T., Li, Z., and Zhou, L. (2022). Prognostic Value of Postoperative Circulating Tumor DNA in Patients with Early- and Intermediate-Stage Hepatocellular Carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.834992"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1097\/JS9.0000000000001236","article-title":"Personalized Circulating Tumor DNA Monitoring Improves Recurrence Surveillance and Management after Curative Resection of Colorectal Liver Metastases: A Prospective Cohort Study","volume":"110","author":"Li","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1158\/1078-0432.CCR-21-0410","article-title":"Minimal Residual Disease Detection Using a Plasma-Only Circulating Tumor DNA Assay in Patients with Colorectal Cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"13261","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of Circulating Tumor DNA in Cholangiocarcinoma Reveals Diagnostic and Prognostic Information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12935-021-02430-9","article-title":"Spatial Maps of Hepatocellular Carcinoma Transcriptomes Highlight an Unexplored Landscape of Heterogeneity and a Novel Gene Signature for Survival","volume":"22","author":"Zhao","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"eabg3750","DOI":"10.1126\/sciadv.abg3750","article-title":"Comprehensive Analysis of Spatial Architecture in Primary Liver Cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-019-0782-x","article-title":"Heterogeneity of Cancer-Associated Fibroblasts and Roles in the Progression, Prognosis, and Therapy of Hepatocellular Carcinoma","volume":"12","author":"Yin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.7150\/thno.71873","article-title":"Spatial Maps of Hepatocellular Carcinoma Transcriptomes Reveal Spatial Expression Patterns in Tumor Immune Microenvironment","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"101304","DOI":"10.1016\/j.jhepr.2024.101304","article-title":"Unraveling the Immune-Activated Tumor Microenvironment Correlated with Clinical Response to Atezolizumab plus Bevacizumab in Advanced HCC","volume":"7","author":"Lim","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/HEP.0000000000000673","article-title":"Single-Cell Dissection of the Multicellular Ecosystem and Molecular Features Underlying Microvascular Invasion in HCC","volume":"79","author":"Li","year":"2024","journal-title":"Hepatology"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability","volume":"44","author":"Mlecnik","year":"2016","journal-title":"Immunity"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"eadm8841","DOI":"10.1126\/sciadv.adm8841","article-title":"Spatially Resolved Immune Exhaustion within the Alloreactive Microenvironment Predicts Liver Transplant Rejection","volume":"10","author":"Barbetta","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41698-024-00640-8","article-title":"Spatial Tumor Immune Microenvironment Phenotypes in Ovarian Cancer","volume":"8","author":"Mateiou","year":"2024","journal-title":"npj Precis. Onc."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-D\u00edaz, G., S\u00e1nchez-Lorencio, M.I., I\u00f1arrairaegui, M., Gonz\u00e1lez-Di\u00e9guez, M.L., Cadah\u00eda, V., Otero-Ferreiro, A., V\u00e1zquez-Mill\u00e1n, M.\u00c1., Romero-Crist\u00f3bal, M., Salcedo, M., and Lorente-P\u00e9rez, S. (2025). Longitudinal Biomarker Progression and Validation for Predicting Operational Tolerance in a Prospective Multicenter Liver Transplantation Immunosuppression Withdrawal Trial. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0326442"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3579\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:58:36Z","timestamp":1779109116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":239,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15103579"],"URL":"https:\/\/doi.org\/10.3390\/jcm15103579","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]}}}